Alpha 1- Proteinase Inhibitor ( Human ) @- Respiratory Enzymes- Nasal Decongestants
Drug Name:
Alpha 1- Proteinase Inhibitor ( Human ) @- Respiratory Enzymes- Nasal Decongestants
List Of Brands:
Indication Type Description:
Adverse Reaction:
Prolastin - delayed fever ( max temp rise was 38.9 C, resolved spontaneously after 24 hours
Mild transcient leukocytosis and dilutional anema several hours after infusion have also been noted.
Contra-Indications:
Severe reactions including anaphylaxis have occured
Special Precautions-
Possibility of unknown infectious agents may be present because alpha P1 is derived from pooled
human plasma . It may carry risk of transmitting infectious agents eg viruses .
Patients may develop signs and symptoms of some viral infection, particularly hepatitis C
All signs and symptoms of infections should be reported.
Circulatory overload- there will be an increase in plasma volume following IV administration.
Use caution in patients at risk of circulatory overload
Hepatitis B immuninazation- it is recommended that in preparation of patients for receiving Prolastin,
recipients be immunized against hepatitis B using hepatitis B vaccine.
Hypersensitivity reactions- if anaphylactic or severe anaphylactoid reactions occur, discontinue
infusion immediately. Ephedrine or other appropiate supportive therapy should be made available
Pregnancy- use only when clearly needed and when the potential benefit outweighs the potential
risk to the fetus.
Lactation- excercise caution when administering to a nursing woman
Children- safety and efficacy for use in children not established
Dosages/ Overdosage Etc:
Indication-
Emphysema
Dosage-
Recommended dosage is 60mg/kg/ body weight administered by IV injection
For IV use only- give at the rate of approx 0.08ml/kg/min as determined by the response
and comfort of patient. The infusion should take approximately 15 to 30 minutes to cpmplete
Patient Information:
1. Inform patients of the signs and symptoms of hypersensitivity reactions including hives,
generalized urticaria, tightness of the chest, dyspnea, wheezing, faintess, hypotension,
and anaphylaxis
2. Advice patients to discontinue use and report to the doctor immediately if any hypersensitivity
reactions takes place.
Pregnancy and lactation:
Pregnancy-
Use only when clearly needed and when the potential benefit outweigh the potential
risk to the fetus.
Lactation-
Excercise caution when administering to a nursing woman
Children-
Safety and efficacy for use in children not established